NASDAQ:ACOR
Delisted

Acorda Therapeutics Stock News

etoro logo Buy ACOR
*Your capital is at risk
$0.661
+0 (+0%)
At Close: Jul 10, 2024
Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandem
Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2020.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 5.) Arcturus Therapeutics Ltd (...
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Bank of America Corp DE lifted its stake in shares of Acorda Therapeutics Inc (NASDAQ:ACOR) by 306.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The in
Lissette Serrano pidió una mascarilla cuando trabajaba limpiando inodoros y recogiendo basura en unas transitadas instalaciones para descansar en una autopista en Connecticut. Le dijeron que no habí
Lissette Serrano is one of about 3,000 cleaners in New York’s Hudson Valley and Connecticut’s Fairfield County put themselves in harm’s way to disinfect public areas with little protective equip
Many cleaners of businesses in the New York area have lost their jobs because buildings have shut or because they refuse to work after getting coronavirus symptoms while on the job
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE